Scientific Symposia
Cryptococcal infections in HIV-infected patients: what is new in 2014?
Epidemiology and microbiology of Cryptococcus spp. in HIV-infected patients
Clinical manifestations of cryptococcal disease and cryptococcal-IRIS
Advances in antifungal therapy of cryptococcal infections
Antiretroviral therapy of patients with AIDS-associated cryptococcosis: when to start and what to start with
Co-Organiser: EFISG, European AIDS Clinical Society
The hidden Beijing M. tuberculosis pandemic
Rapid detection of Beijing genotype
Resistance of Beijing tuberculosis
Treatment and hospital management of contagious multiresistant Beijing tuberculosis pulmonary infection
Selective advantages of the Beijing genotype of Mycobacterium tuberculosis
Carbapenemases from prevention to treatment
Carbapenemases from (not) detection to control
Update on OXA carbapenemases
NDM dissemination
KPC around the world
Co-Organiser: ESGARS
Why are some carbapenemases successful?
Why are some carbapenemases more successful than others?
Beta-lactamase and breakpoints: do we have the right ones?
Case-based decisions in the era of XDR Gram-negatives: towards individualised therapy?
Empirical therapy for MDR and XDR Gram-negatives
Definitive therapy for ESBL-producers: life beyond carbapenems?
Definitive therapy for carbapenemase-producing Enterobacteriaceae: MIC matters?
XDR-Pseudomonas aeruginosa and Acinetobacter
Combined antimicrobial therapy for multi-resistant Gram-negative bacteria
Aminoglycosides used in combined treatment for multi-resistant Gram-negative bacteria
Combined therapy for carbapenemase-producing Klebsiella pneumoniae
Combined therapy for carbapenemase-producing Pseudomonas aeruginosa
Combined therapy for carbapenemase-producing Acinetobacter baumannii
Co-Organiser: ESGARS
Uncertainties in transplant vaccination
Conjugated pneumococcal vaccine in stem cell and solid organ transplant recipients
What can be expected from cytomegalovirus vaccine?
Other vaccines beside pneumococcal, influenza, and CMV. What is new in the transplant setting?
Influenza vaccination. How can we improve its effectiveness?
Can we treat Gram-negative bacteraemia with a short-course of antibiotics? Pro/Con debate
Ins and outs of Legionnaires Disease
Diagnosis of Legionnaires Disease
Treatment of Legionnaires Disease
Epidemiology of travel-associated Legionnaires Disease
Prevention and control of Legionnaires Disease
Co-Organiser: ESGLI, European Centre for Disease Control (ECDC)
Macrolides are still safe and effective to be used in clinical practice. Pro/Con debate
Yes, we can use them unequivocally
Beware! Too many drug interactions and side effects...
What is new in immunocompromised patients?
Innate immunity and infections in transplant patients - new insights
CMV infections: new options for clinical management
Clinical relevance of respiratory viruses in immunocompromised patients
Emerging bacterial resistance and its impact on therapy in cancer patients
Co-Organiser: International Immunocompromised Host Society (ICHS)
Improving empirical antibiotic treatment in hospital
The contribution of rapid diagnostic techniques to current clinical practice
What are we trying to improve: long-term outcomes of sepsis
Does appropriate empirical antibiotic treatment improve outcomes for infections caused by MDR bacteria?
Ecological use of antibiotics. Is it possible?
Staphylococcus aureus bacteraemia: controversial issues
Pathogenesis of complicated SAB: pathogen, host, or both?
Complicated SAB: who we should be worried about and how to evaluate
Combined therapy versus monotherapy. Any news?
Vancomycin MIC in MSSA and MRSA. What does it mean and does it really matter?
Co-Organiser: ESGBIS
Mycobacteria in cutaneous infections
Buruli ulcer due to M. ulcerans
Leprosy: the old and new leprosy bacilli
Co-Organiser: ESGMYC
Hot topics in vaccine-preventable diseases
Measles and rubella eradication
Vaccine pipeline in China: current achievements and bright future
Reducing the burden of pneumococcal disease with pneumococcal conjugate vaccines
Use of conjugate vaccines for prevention of meningococcal disease
Co-Organiser: EVASG
Ticks and tick-borne pathogens
Lyme disease: from bench to bedside
Rickettsial infection
Tick-borne encephalitis
Emerging tick-borne viral infections
Co-Organiser: ESCAR, ESGBOR
Emergence of Clostridium difficile infections outside healthcare facilities
Clostridium difficile in food and in production animals
Risk factors and a clinical prediction score for CDI acquired in the community
Co-Organiser: ESGCD
Prevention of surgical site infections: time to recast?
Etiology and consequences of surgical site infections
When do you need to administer the prophylaxis?
Surgical antimicrobial prophylaxis in solid organ transplantation (SOT): which antibiotic for which microorganism?
Is it necessary to modify the prophylaxis in surgery with foreign body implantation?
What is new on surgical site infection prevention?
The burden and prevention of SSI: a global perspective from WHO
The CDC/HICPAC recommendations for SSI prevention: what is new after 15 years?
Barriers to implementing good antibiotic prophylaxis and how to overcome them
Controversial issues in the prevention of surgical site infections
Going away from blood: why not to test oral fluid and urine?
Oral fluid testing in microbiology
Urine testing in microbiology
Forensic and post-mortem microbiology in the 21st century
Forensic and autopsy microbiology: general overview and current challenges
Microbiological testing of tissues and cells for transplantation: practical guidelines
Sudden unexpected death in infancy and childhood: how frequent is infectious etiology?
Looking for microbes in paraffin blocks and other archival clinical samples
Co-Organiser: Future ESCMID study group on forensic microbiology
Application of new methods in medical microbiology and infection control
Next-generation sequencing: a one-stop shop for bacterial identification, antimicrobial susceptibility testing, virulence and subtyping?
Infection control within healthcare communities: using modern technology and network analysis
Modern diagnostics in the developing world
Detecting polymicrobial causes of infections
Co-Organiser: ESGEM, ESGMD, ESGNI
Laboratory response to emerging viral diseases: from pathogen discovery to disease monitoring
Discovery and epizootic investigation of Schmallenberg virus infections in livestock
Discovery of Middle-East respiratory syndrome coronavirus and development of diagnostics
Investigation of avian influenza A(H7N9) emergence in China
Monitoring emerging infectious diseases: role of public health laboratory networks
Co-Organiser: European Centre for Disease Control (ECDC)
Full laboratory automation
Advantages and limitations of the different full lab automated systems for bacteriology
What to take into consideration when planning to move towards full lab automation?
Microbiology modernisation and rationalisation: a professional challenge
Information technology and automation: ground floor view from London
Infections and devices: imaging & nuclear medicine meets infectious diseases
Bone and prosthetic joint infections: what the infectious disease specialist needs
Bone and prosthetic joint infections: the point of view of the nuclear medicine specialist
Endocarditis: what the infectious disease specialist needs
Endocarditis: how imaging and nuclear medicine can help
Co-Organiser: European Association of Nuclear Medicine (EANM)
Molecular diagnosis: commercial or home-made tests - Pro/Con debate
Molecular diagnosis should be done using CE-marked commercial kits
Molecular diagnosis should be done using home-made test
Surveillance of healthcare-associated infections: infections or procedures?
Infections
Procedures
Implementing international guidelines to reduce the spread of MDR Gram-negatives at national level
Agreements and disagreements from international guidance documents
Identifying and tackling the challenges in local application
How to measure success of implementing guidelines
Limitations of extracting the evidence for guidelines in infection control
Controlling transmission of multidrug-resistant pathogens in the intensive care unit
Decolonisation options for MRSA, VRE, ESBL and CPE: efficacy and safety
Effectiveness of MDRO decolonisation: epidemiological and clinical determinants
MDRO screening and targeted decolonisation strategy
Universal decolonisation strategy
The year in Infection Control
Listeria and listeriosis
Listeria genomics
Listeriosis: a prospective study of 800 cases
Making sense of our relationships with mucosal commensals and pathogens
Streptococcus pneumoniae colonisation of the human host and transmission
Shigella and the gut: an inflamed debate
The specificity of Salmonella enterica Typhi for humans: uncovering cell and host restriction factors
Understanding Neisseria menigitidis pathogenesis to design and evaluate meningococcal vaccines
Co-Organiser: Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Optimisation of empirical and targeted antifungal therapy for invasive aspergillosis
Persistent febrile neutropenia: diagnostic-driven antifungal therapy vs. empirical antifungal therapy
Therapeutic monitoring of drug levels for invasive aspergillosis
First-line therapy with combined antifungal for aspergillosis
Salvage therapy of invasive aspergillosis refractory to primary therapy with voriconazole
T-cells in invasive aspergillosis
Pathogenicity
Therapy
Co-Organiser: EFISG
Predicting the future in fungal diagnosis and therapy
Non-cultural methods for aspergillosis
Candidal diagnostic tests
New cryptococcal and histoplasmosis tests
Designing new diagnostic-driven therapy concepts
Co-Organiser: EFISG, Mycology Study Group of the International Society for Human and Animal Mycology (MSG)
Acute anaemia after treatment of malaria with intravenous artesunate - a new variant of "blackwater fever"?
Acute anaemia after treatment of malaria with intravenous artesunate
Haemolysis in USA patients treated with intravenous artesunate
Co-Organiser: ESGCP
An update on leishmaniasis
Global epidemiology of leishmaniasis. Where are the hot spots?
Infection vs disease - aspmytomatic carriers and risk factors for reactivation and recurrence
Diagnosis: monitoring outcome
Treatment options: evidence-based recommendations for different Leishmania spp
Co-Organiser: ESGCP
Diagnostic tools in parasitology
Advantages of mass spectrometry over microscopy
Benefits of PCR and microscopy, and its combinations, in diagnostic parasitology
Co-Organiser: ESGCP
What is hot in HIV in 2014?
Toward a functional HIV cure
Immunological control in HIV infection: is it achievable?
When to start HIV treatment?
HIV therapy: what is in the pipeline in 2014?
HIV and hepatitis C co-infection: double trouble?
HIV-HCV co-infection: wait or treat?
Interferon-free treatment for chronic hepatitis C - how and when?
The challenge of respiratory viruses
Diagnostic challenges: speed, loads and multiplex
Emerging respiratory viruses
Vaccination and treatment
Infection control of respiratory viruses: global and local
Viral opportunists in the critically ill patient
Basic aspects of cytomegalovirus subversion and immune control
Clinical science: when to ignore, observe or treat?
Nebulised antibiotics: challenge for 2014
Nebulisers and technique of administration
Pharmacokinetics and pharmacodynamics of nebulised antimicrobials
Nebulised antibiotics for mechanically-ventilated patients
Nebulised antibiotics in cystic fibrosis and brochiectasis
Co-Organiser: ESGCIP
Two-faced companions: highlights in the world of anaerobes
More than a nasty smell - burden of emerging anaerobes in the era of molecular detection
Escape from the biofilm – disseminated oral anaerobic infections
Anaerobes in medical device infections - a failed diagnosis?
Anaerobes in sinusitis and chronic respiratory tract infections
Co-Organiser: ESGAI, Society for Anaerobic Microbiology
Great scientific success with scarce resources. Is money issue a crucial point?
Scientific career in adverse economic and social conditions
Research in extraordinary times of war
Co-Organiser: Parity Commission, TAE
The Good, the Bad and the Ugly: recently approved and developmental anti-bacterials
Developmental beta-lactamase inhibitors in phase 2/3 clinical trials
Ceftaroline
Fidaxomicin
Tigecycline
Co-Organiser: EPASG
PK/PD - the merits of models and measurement
Pre-clinical in vitro models
Pre-clinical in vivo models
Measurement of beta-lactams in serum
Value of the measurement of antibiotic concentration in tissues
Co-Organiser: EPASG
Colistin: position in the era of multi-resistance
PK/PDs and susceptibility testing: are we far from the correct direction?
The polymyxin resistome
Efficacy issues: clinical evidence on monotherapy and combination therapies
Challenges of clinical trials in critically ill patients: the Prato Consensus
Training in infection in Europe – progress in curricula and assessments
Training in infectious diseases
Training in clinical microbiology
Trainees viewpoints and survey results
Co-Organiser: TAE, Professional Affairs Subcommittee, UEMS-ID, UEMS-MM
Bacterial persistence and tolerance: from bench to bedside
Molecular basis of bacterial persistence and tolerance
Microbiological insights into heteroresistance and persistence in Gram-negative bacteria
Clinical relevance of bacterial persistence and tolerance
Novel strategies for eradication of persister cells
Exploring and treating biofilms
Bacterial biofilms in VAP: implications for diagnosis and treatment
Dissecting the S. aureus biofilmome
Anti-biofilm agents: where are we?
In vitro models for the study of antibiotic PK/PD in biofilms
New approaches to prevent transmission of Clostridium difficile infections
What is the protective factor of the microbiota?
Does antimicrobial stewardship and specific Clostridium difficile antimicrobial prophylaxis prevent CDI?
What is the role of asymptomatic patients and other reservoirs in acquisition of CDI?
How to eradicate Clostridium difficile spores from the environment?
Co-Organiser: ESGCD
The Year in Clinical Microbiology
The Year in Infectious Diseases